FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2043137079> ?p ?o ?g. }

• W2043137079 endingPage "2037" @default.
• W2043137079 startingPage "2032" @default.
• W2043137079 abstract "Hepatocellular carcinoma (HCC) is an increasingly lethal malignancy for which management is critically dependent on accurate imaging. Glypican-3 (GPC3) is a cell surface receptor overexpressed in most HCCs and provides a unique target for molecular diagnostics. The use of monoclonal antibodies (mAbs) that target GPC3 (αGPC3) in PET imaging has shown promise but comes with inherent limitations associated with mAbs such as long circulation times. This study used (89)Zr-conjugated F(ab')2 fragments directed against GPC3 ((89)Zr-αGPC3-F(ab')2) to evaluate the feasibility of the fragments as a diagnostic immuno-PET imaging probe.Immobilized ficin was used to digest αGPC3, creating αGPC3-F(ab')2 fragments subsequently conjugated to (89)Zr. In vivo biodistribution and PET studies were performed on GPC3-expressing HepG2 and GPC3-nonexpressing RH7777 orthotopic xenografts.Reliable αGPC3-F(ab')2 production via immobilized ficin digestion was verified by high-performance liquid chromatography and sodium dodecyl sulfate polyacrylamide gel electrophoresis. (89)Zr-αGPC3-F(ab')2 demonstrated F(ab')2-dependent, antigen-specific cell binding. HepG2 tumor uptake was higher than any other tissue, peaking at 100 ± 21 percentage injected dose per gram (%ID/g) 24 h after injection, a value 33- to 38-fold higher than GPC3-nonexpressing RH7777 tumors. The blood half-life of the (89)Zr-αGPC3-F(ab')2 conjugate was approximately 11 h, compared with approximately 115 h for historic mAb controls. This shorter half-life enabled clear tumor visualization on PET 4 h after administration, with a resultant peak tumor-to-liver contrast ratio of 23.3. Blocking antigen-expressing tumors with an excess of nonradiolabeled αGPC3 resulted in decreased tumor uptake similar to native liver. The kidneys exhibited high tissue uptake, peaking at 24 h with 83 ± 12 %ID/g. HepG2 tumors ranging from 1.5 to 7 mm were clearly visible on PET, whereas larger RH7777 tumors displayed signal lower than background liver tissue.This study demonstrates the feasibility of using (89)Zr-αGPC3-F(ab')2 for intrahepatic tumor localization with small-animal PET. Faster blood clearance and lower background liver uptake enable excellent signal-to-noise ratios at early time points. Increased renal uptake is similar to that as has been seen with clinical radioactive peptide imaging. (89)Zr-αGPC3-F(ab')2 addresses some of the shortcomings of whole-antibody immuno-PET probes. Further optimization is warranted to maximize probe sensitivity and specificity in the process of clinical translation." @default.
• W2043137079 created "2016-06-24" @default.
• W2043137079 creator A5007318813 @default.
• W2043137079 creator A5010045362 @default.
• W2043137079 creator A5036889393 @default.
• W2043137079 creator A5053526360 @default.
• W2043137079 creator A5061782765 @default.
• W2043137079 creator A5072719883 @default.
• W2043137079 creator A5072866393 @default.
• W2043137079 creator A5077460554 @default.
• W2043137079 creator A5082164835 @default.
• W2043137079 date "2014-10-30" @default.
• W2043137079 modified "2023-10-17" @default.
• W2043137079 title "Glypican-3–Targeting F(ab′)2 for ⁸⁹Zr PET of Hepatocellular Carcinoma" @default.
• W2043137079 cites W1580407891 @default.
• W2043137079 cites W1589490029 @default.
• W2043137079 cites W1604355109 @default.
• W2043137079 cites W1974682739 @default.
• W2043137079 cites W1988743717 @default.
• W2043137079 cites W1993093755 @default.
• W2043137079 cites W2000656127 @default.
• W2043137079 cites W2017745942 @default.
• W2043137079 cites W2018897774 @default.
• W2043137079 cites W2043201198 @default.
• W2043137079 cites W2044366912 @default.
• W2043137079 cites W2048490035 @default.
• W2043137079 cites W2052699946 @default.
• W2043137079 cites W2054956474 @default.
• W2043137079 cites W2078600724 @default.
• W2043137079 cites W2084952307 @default.
• W2043137079 cites W2109842079 @default.
• W2043137079 cites W2115269770 @default.
• W2043137079 cites W2116323192 @default.
• W2043137079 cites W2122767481 @default.
• W2043137079 cites W2125410856 @default.
• W2043137079 cites W2127145736 @default.
• W2043137079 cites W2128551196 @default.
• W2043137079 cites W2130870133 @default.
• W2043137079 cites W2131605375 @default.
• W2043137079 cites W2142698513 @default.
• W2043137079 cites W2153750906 @default.
• W2043137079 cites W2166062026 @default.
• W2043137079 cites W4299546478 @default.
• W2043137079 cites W4319290869 @default.
• W2043137079 doi "https://doi.org/10.2967/jnumed.114.145102" @default.
• W2043137079 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4259878" @default.
• W2043137079 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25359880" @default.
• W2043137079 hasPublicationYear "2014" @default.
• W2043137079 type Work @default.
• W2043137079 sameAs 2043137079 @default.
• W2043137079 citedByCount "52" @default.
• W2043137079 countsByYear W20431370792015 @default.
• W2043137079 countsByYear W20431370792016 @default.
• W2043137079 countsByYear W20431370792017 @default.
• W2043137079 countsByYear W20431370792018 @default.
• W2043137079 countsByYear W20431370792019 @default.
• W2043137079 countsByYear W20431370792020 @default.
• W2043137079 countsByYear W20431370792021 @default.
• W2043137079 countsByYear W20431370792022 @default.
• W2043137079 countsByYear W20431370792023 @default.
• W2043137079 crossrefType "journal-article" @default.
• W2043137079 hasAuthorship W2043137079A5007318813 @default.
• W2043137079 hasAuthorship W2043137079A5010045362 @default.
• W2043137079 hasAuthorship W2043137079A5036889393 @default.
• W2043137079 hasAuthorship W2043137079A5053526360 @default.
• W2043137079 hasAuthorship W2043137079A5061782765 @default.
• W2043137079 hasAuthorship W2043137079A5072719883 @default.
• W2043137079 hasAuthorship W2043137079A5072866393 @default.
• W2043137079 hasAuthorship W2043137079A5077460554 @default.
• W2043137079 hasAuthorship W2043137079A5082164835 @default.
• W2043137079 hasBestOaLocation W20431370791 @default.
• W2043137079 hasConcept C150903083 @default.
• W2043137079 hasConcept C153911025 @default.
• W2043137079 hasConcept C159654299 @default.
• W2043137079 hasConcept C185592680 @default.
• W2043137079 hasConcept C202751555 @default.
• W2043137079 hasConcept C203014093 @default.
• W2043137079 hasConcept C207001950 @default.
• W2043137079 hasConcept C2777807558 @default.
• W2043137079 hasConcept C2778019345 @default.
• W2043137079 hasConcept C2779742787 @default.
• W2043137079 hasConcept C2989005 @default.
• W2043137079 hasConcept C502942594 @default.
• W2043137079 hasConcept C542903549 @default.
• W2043137079 hasConcept C55493867 @default.
• W2043137079 hasConcept C71924100 @default.
• W2043137079 hasConcept C86803240 @default.
• W2043137079 hasConceptScore W2043137079C150903083 @default.
• W2043137079 hasConceptScore W2043137079C153911025 @default.
• W2043137079 hasConceptScore W2043137079C159654299 @default.
• W2043137079 hasConceptScore W2043137079C185592680 @default.
• W2043137079 hasConceptScore W2043137079C202751555 @default.
• W2043137079 hasConceptScore W2043137079C203014093 @default.
• W2043137079 hasConceptScore W2043137079C207001950 @default.
• W2043137079 hasConceptScore W2043137079C2777807558 @default.
• W2043137079 hasConceptScore W2043137079C2778019345 @default.
• W2043137079 hasConceptScore W2043137079C2779742787 @default.
• W2043137079 hasConceptScore W2043137079C2989005 @default.

• next